Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(3-Guanidinophenyl)-3-mercaptopropanoic acid is a synthetic small molecule belonging to the class of benzene and substituted derivatives, specifically aromatic homomonocyclic compounds. It features a guanidino group attached to a phenyl ring and a mercaptopropanoic acid moiety. The compound has been studied as an experimental agent with potential biological activity, notably as an inhibitor of certain enzymes. Its mechanism of action is reported as an inhibitor (target unspecified in public sources), but it has been referenced in research related to enzyme inhibition and drug repurposing efforts[1][2][3][9]. There are no approved therapeutic indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(3-guanidinophenyl)-3-mercaptopropanoic acid.